A subgroup analysis of the BIO-RESORT trial has shown a “trend towards better outcomes” with thinner strut stents in patients with small vessels (<2,5mm) undergoing percutaneous coronary intervention (PCI).

Transit Scientific had shared via press release successful outcomes on multiple fistula and graft cases using its XO Score sheath platform, a first-of-its-kind metal-alloy scoring, cutting, and constraining structure (CS) device, along with off-the-shelf percutaneous transluminal angioplasty (PTA) balloons.

A University of Texas at Arlington (UTA; Arlington, USA) bioengineer is leading a project that will develop biodegradable nanomaterials that will take pictures and deliver medicine to combat peripheral arterial disease (PAD), the university announced in a press release.

HeartBeam is expanding the available patient population for its emergency department software technology solution. In evaluating the electrocardiogram (ECG) database for the clinical validation of HeartBeam’s platform technology, a significant portion of consecutive patients fell into the category of unstable angina.

The most read stories from across Cardiovascular News in June 2022 include highlights from TVT 2022 (The Structural Heart Summit, 8–10 June, Chicago, USA), an interview with the creator of the first transcatheter aortic valve, a new treatment to reduce stroke and heart attack deaths and data from the UK TAVI trial.

Advanced NanoTherapies has closed a US$7.2 million Series A equity financing round marking a total of US$12.5 million raised since September 2020. Funds will be used to complete the first-in-human clinical study in Australia of the SirPlux Duo drug-coated balloon (DCB) in de novo coronary artery disease (CAD) lesions. Funding comes from sources in the USA, Canada, Europe and Asia.

Results from the first commercial implants of the Trilogy transcatheter aortic valve implantation (TAVI) system (Jenavalve) for high-surgical risk patients with severe, symptomatic aortic stenosis (AS) or aortic regurgitation (AR) were reported at EuroPCR 2022 (17–20 May, Paris, France)

Teleflex has announced the first patient enrolment in a clinical study that is intended to demonstrate the safety of the Manta vascular closure device using ultrasound guidance, without dependence on preprocedural depth locator measurements. The study will enroll patients undergoing elective transcatheter aortic valve implantation (TAVI) procedures with planned percutaneous femoral arterial access.

Conformal Medical has announced the launch of the CONFORM pivotal trial with the enrolment of the first patients at two US sites.

The National Institute for Health and Care Excellence (NICE) has recommended the use of VAZKEPA (icosapent ethyl; Amarin) in adult statin-treated patients at high cardiovascular risk who have elevated triglycerides (≥150 mg/dL [≥ 1.7 mmol/L]), LDL-C levels >1.04 mmol/L (and ≤ 2.60 mmol/L) and established cardiovascular disease (CVD).1,2 The final guidance is expected to be available on 20 July 2022.

In a study of over 7,000 chronic limb-threatening ischaemia (CLTI) patients, researchers found that Black and Hispanic patients had higher three-year amputation and reintervention rates; survival, however, was higher among Black patients and similar between Hispanic and White patients. Aderike Anjorin (Duke University Medical Center, Durham, USA) delivered these findings at this year’s Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM 2022; 15–18 June, Boston, USA).

Transcatheter aortic valve implantation (TAVI) with the Acurate neo2 (Boston Scientific) device was associated with a lower prevalence of moderate or severe paravalvular aortic regurgitation (AR) and more patients with no or trace paravalvular AR compared with an earlier-generation device—a difference that was particularly evident in patients with heavy aortic valve calcification.